JAK2 and myelofibrosis: Several explanations may account for the relatively disappointing results, including the genetic complexity of myelofibrosis, suppression of residual normal hematopoiesis as a result of JAK2 inhibition and the relatively low potency of available JAK2 inhibitors [75,76].